enGene Therapeutics Inc.
ENGNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Other share classesENGN
Q3 2024 vs. Q2 2024
How the institutions holding enGene Therapeutics Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 16 | 14 | −2 |
| Shares | 4.91M | 5.24M | +325.5K (+6.6%) |
| Value | $6.54M | $9.20M | +$2.67M (+40.8%) |
New holders (0)
Institutions that held enGene Therapeutics Inc. at the end of Q3 2024 but not at the end of Q2 2024.
None.
Sold out (2)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Wolverine Asset Management LLC | 28,197 | $33.6K |
| Polar Asset Management Partners Inc. | 97,391 | $0 |